Fernando Jerkovich1, María Gabriela García Falcone1, Fabián Pitoia2. 1. Division of Endocrinology, University of Buenos Aires, Buenos, Aires, Argentina. 2. Division of Endocrinology, University of Buenos Aires, Buenos, Aires, Argentina. fpitoia@intramed.net.
Abstract
PURPOSE: To describe the experience of our Division of Endocrinology with multikinase inhibitor (MKI) treatment in radioiodine-resistant differentiated thyroid cancer (DTC) patients. METHODS: Adults patients with a diagnosis of DTC treated with an MKI drug from March 2011 to October 2018 were registered into a retrospective database. Primary objectives were: the assessment of progression-free survival (PFS) and radiographic response evaluated according to RECIST v. 1.1. Adverse events (AEs) were evaluated by using Common Terminology Criteria for Adverse Events v. 5.0. RESULTS: Twenty-two patients were treated with MKIs (21 with sorafenib, one with lenvatinib as first-line treatment). Seven patients required a second-line therapy with lenvatinib and one patient required a third-line treatment with pazopanib. Median duration of treatment was 11.2 (4.8-79.6) months. Best responses with sorafenib were partial response (PR) in two patients (11%), stable disease (SD) >6 months in 13 patients (72%), and progressive disease (PD) in three patients (17%). Best responses with second-line lenvatinib were PR in one patient (33%) and SD in two patients (66%). Median PFS was 31.5 months. AEs were present in 19 (90%) patients under sorafenib. The most common AEs were hand-foot syndrome (HFS) (67%), diarrhea (52%), and hypertension (52%). Definitive withdrawal was necessary in only one patient (4.7%). CONCLUSIONS: Our study reflects the real-world clinical experience of an Endocrinology Division on the management of radioiodine-resistant DTC patients with sorafenib and lenvatinib, showing a beneficial therapeutic effect with acceptable tolerability.
PURPOSE: To describe the experience of our Division of Endocrinology with multikinase inhibitor (MKI) treatment in radioiodine-resistant differentiated thyroid cancer (DTC) patients. METHODS: Adults patients with a diagnosis of DTC treated with an MKI drug from March 2011 to October 2018 were registered into a retrospective database. Primary objectives were: the assessment of progression-free survival (PFS) and radiographic response evaluated according to RECIST v. 1.1. Adverse events (AEs) were evaluated by using Common Terminology Criteria for Adverse Events v. 5.0. RESULTS: Twenty-two patients were treated with MKIs (21 with sorafenib, one with lenvatinib as first-line treatment). Seven patients required a second-line therapy with lenvatinib and one patient required a third-line treatment with pazopanib. Median duration of treatment was 11.2 (4.8-79.6) months. Best responses with sorafenib were partial response (PR) in two patients (11%), stable disease (SD) >6 months in 13 patients (72%), and progressive disease (PD) in three patients (17%). Best responses with second-line lenvatinib were PR in one patient (33%) and SD in two patients (66%). Median PFS was 31.5 months. AEs were present in 19 (90%) patients under sorafenib. The most common AEs were hand-foot syndrome (HFS) (67%), diarrhea (52%), and hypertension (52%). Definitive withdrawal was necessary in only one patient (4.7%). CONCLUSIONS: Our study reflects the real-world clinical experience of an Endocrinology Division on the management of radioiodine-resistant DTCpatients with sorafenib and lenvatinib, showing a beneficial therapeutic effect with acceptable tolerability.
Authors: Thomas E Hutson; Joaquim Bellmunt; Camillo Porta; Cezary Szczylik; Michael Staehler; Andrea Nadel; Sibyl Anderson; Ronald Bukowski; Tim Eisen; Bernard Escudier Journal: Eur J Cancer Date: 2010-07-23 Impact factor: 9.162
Authors: M Molina-Vega; J García-Alemán; A Sebastián-Ochoa; I Mancha-Doblas; J M Trigo-Pérez; F Tinahones-Madueño Journal: Endocrine Date: 2017-12-23 Impact factor: 3.633
Authors: Laurie L Carr; David A Mankoff; Bernardo H Goulart; Keith D Eaton; Peter T Capell; Elizabeth M Kell; Julie E Bauman; Renato G Martins Journal: Clin Cancer Res Date: 2010-09-16 Impact factor: 12.531
Authors: Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman Journal: N Engl J Med Date: 2015-02-12 Impact factor: 91.245
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ramona Dadu; Catherine Devine; Mike Hernandez; Steven G Waguespack; Naifa L Busaidy; Mimi I Hu; Camilo Jimenez; Mouhammad A Habra; Rena V Sellin; Anita K Ying; Gilbert J Cote; Steven I Sherman; Maria E Cabanillas Journal: J Clin Endocrinol Metab Date: 2014-03-14 Impact factor: 5.958
Authors: Rajan P Dang; Daniel McFarland; Valerie H Le; Nadia Camille; Brett A Miles; Marita S Teng; Eric M Genden; Krzysztof J Misiukiewicz Journal: Int J Surg Oncol Date: 2016-09-22
Authors: C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald Journal: Endocrine Date: 2020-03-16 Impact factor: 3.633
Authors: Anne Christine Kaae; Michael C Kreissl; Marcus Krüger; Manfred Infanger; Daniela Grimm; Markus Wehland Journal: Int J Mol Sci Date: 2021-11-12 Impact factor: 5.923
Authors: Ole Vincent Ancker; Marcus Krüger; Markus Wehland; Manfred Infanger; Daniela Grimm Journal: Int J Mol Sci Date: 2019-12-18 Impact factor: 5.923